Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Status: Enrolling
Updated:  3/15/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Status: Enrolling
Updated: 3/15/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Status: Enrolling
Updated:  3/15/2018
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Status: Enrolling
Updated: 3/15/2018
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Indiana University Health
mi
from
Goshen, IN
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Indiana University Health
mi
from
Goshen, IN
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Maryland Oncology Hematology, P.A.
mi
from
Rockville, MD
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Maryland Oncology Hematology, P.A.
mi
from
Rockville, MD
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Mount Sinai Beth Israel
mi
from
New York, NY
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Mount Sinai Beth Israel
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Medical University of South Carolina
mi
from
Charleston, SC
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)
A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)
A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
mi
from
Los Angeles, CA
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
mi
from
Ottawa,
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
mi
from
Ottawa,
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
mi
from
Portland, OR
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
mi
from
Portland, OR
Click here to add this to my saved trials
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated:  3/15/2018
Northwestern University
mi
from
Chicago, IL
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated: 3/15/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated:  3/15/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated: 3/15/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Click here to add this to my saved trials
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated:  3/15/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated: 3/15/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
Yale Universtiy
mi
from
New Haven, CT
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
Yale Universtiy
mi
from
New Haven, CT
Click here to add this to my saved trials
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Reducing Disability in Older Adult Cancer Survivors
A Phase I Randomized Controlled Trial of a Problem-solving Occupational Therapy Intervention for Older Adult Cancer Survivors
Status: Enrolling
Updated:  3/16/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Reducing Disability in Older Adult Cancer Survivors
A Phase I Randomized Controlled Trial of a Problem-solving Occupational Therapy Intervention for Older Adult Cancer Survivors
Status: Enrolling
Updated: 3/16/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Indocyanine Green for Solid Tumors
A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green
Status: Enrolling
Updated:  3/16/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Indocyanine Green for Solid Tumors
A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green
Status: Enrolling
Updated: 3/16/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer
Status: Enrolling
Updated:  3/16/2018
Georgetown University Hospital
mi
from
Washington,
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer
Status: Enrolling
Updated: 3/16/2018
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Minimally Invasive Imagery With Indocyanine Green
A Pilot & Feasibility Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Minimally Invasive Thoracic Surgery Presenting With Thoracic Nodules
Status: Enrolling
Updated:  3/16/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Minimally Invasive Imagery With Indocyanine Green
A Pilot & Feasibility Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Minimally Invasive Thoracic Surgery Presenting With Thoracic Nodules
Status: Enrolling
Updated: 3/16/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
A Pilot Phase II Study of Pre-Operative Radiation Therapy and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative MAID/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall
Status: Enrolling
Updated:  3/16/2018
Radiation Therapy Oncology Group
mi
from
Philadelphia, PA
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
A Pilot Phase II Study of Pre-Operative Radiation Therapy and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative MAID/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall
Status: Enrolling
Updated: 3/16/2018
Radiation Therapy Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
Des Moines Oncology Research Association
mi
from
Des Moines, IA
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
Des Moines Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Lazanda in Cancer Patients Receiving Palliative Radiation
Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation
Status: Enrolling
Updated:  3/16/2018
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Lazanda in Cancer Patients Receiving Palliative Radiation
Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation
Status: Enrolling
Updated: 3/16/2018
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Aurora, CO
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Chicago, IL
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
New York, NY
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  3/17/2018
Research Site
mi
from
Brescia,
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 3/17/2018
Research Site
mi
from
Brescia,
Click here to add this to my saved trials
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors
Status: Enrolling
Updated:  3/19/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors
Status: Enrolling
Updated: 3/19/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
mi
from
Los Angeles, CA
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
mi
from
New York, NY
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
mi
from
Madison, WI
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute-Albemarle
mi
from
Albemarle, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute-Albemarle
mi
from
Albemarle, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute-South Tryon
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute-South Tryon
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Pineville
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Pineville
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Southpark
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Southpark
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Mallard Creek
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Mallard Creek
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - University
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - University
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Ballantyne
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Ballantyne
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Concord
mi
from
Concord, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Concord
mi
from
Concord, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute-Monroe
mi
from
Monroe, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute-Monroe
mi
from
Monroe, NC
Click here to add this to my saved trials